Home Page: Journal of Thoracic Oncology

Time 2021-01-02 18:04:25

Web Name: Home Page: Journal of Thoracic Oncology

WebSite: http://www.jto.org

ID:154396

Keywords:

Journal,Page,Home,

Description:

Editor's Choice The nineteenth installment in our “Lung Cancer World Wide” series is Lung Cancer in France, by Dr Jean-Louis Pujol and colleagues. This manuscript is an important resource with an excellent overview of lung cancer screening, diagnosis and treatment in France. There is currently controversy over the best approach to the therapy of small cell lung cancer, as questions are raised about the utility and need for prophylactic cranial radiation and consolidative radiation in extensive stage small cell lung cancer. The American Radium Society through their Thoracic Appropriate Use Criteria Committee have developed updated consensus statements for the treatment of limited stage small cell lung cancer (American Radium Society™ Appropriate Use Criteria Radiation Therapy for Limited-stage Small Cell Lung Cancer 2020– Chung SG et al) and extensive stage small cell lung cancer ES-SCLC (American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-stage Small Cell Lung Cancer – Higgins KA et al). These two manuscripts provide a useful overview of the current state of therapy for this disease.In the early days of anti-PDL1 therapy, atezolizumab was evaluated in the second line setting of NSCLC through the phase II POPLAR and phase III OAK studies of atezolizumab versus docetaxel. Both studies demonstrated a survival benefit. In this issue of the journal, Mazieres and colleagues present final overall survival and four-year survival data for both studies. Their report confirms the OS benefit with a longer OS observed in patients receiving atezolizumab vs docetaxel in POPLAR (median OS: 12.6 months vs 9.7 months; HR: 0.76) and OAK (median OS: 13.3 vs 9.8 months; HR: 0.78). Four-year OS rates in POPLAR are 14.8% and 8.1% for atezolizumab and docetaxel, respectively, and 15.5% and 8.7% in OAK. Key takeaways from these studies are that most 4-year survivors in the docetaxel arms received subsequent immunotherapy (POPLAR, 50%; OAK, 65%); most of these long term survivors had non-squamous NSCLC, a good performance status (ECOG PS 0) and approximately half had an objective response to therapy. Lung cancer stigma is known to negatively impact the clinical care and outcomes of patients. King and colleagues sought to determine whether attitudes about lung cancer had changed over a decade. The investigators used the same tools and methodology to perform a cross-sectional survey administered to the general public, oncologists, and lung cancer patients ten years apart (2008 and 2018). Their results, published in this issue of the journal, reflect recognition of treatment gains and increased visibility of lung cancer but also highlight that stigma still remains a significant problem, with an increase in stigma reported by patients. Dr Heidi Hamann and colleagues discuss the implications of these findings in an excellent accompanying editorial.Alex A. Adjei, MD, PhDEditor-in-Chief Lung Cancer in FranceJean-Louis Pujol, Pascal-Alexandre Thomas, Philippe Giraud, Marc G. Denis, Brigitte Tretarre, Benoît Roch, Sebastien BommartDOI: https://doi.org/10.1016/j.jtho.2020.09.012Vol. 16, Issue 1, p21 29American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLCExpert Panel Thoracic Malignancies: Kristin A. Higgins, Charles B. Simone II, Arya Amini, Indrin J. Chetty, Jessica Donington, Martin J. Edelman, Stephen G. Chun, Larry L. Kestin, Benjamin Movsas, George B. Rodrigues, Kenneth E. Rosenzweig, Ben J. Slotman, Igor I. Rybkin, Andrea Wolf, Joe Y. ChangDOI: https://doi.org/10.1016/j.jtho.2020.09.013Vol. 16, Issue 1, p54 65American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020Stephen G. Chun, Charles B. Simone II, Arya Amini, Indrin J. Chetty, Jessica Donington, Martin J. Edelman, Kristin A. Higgins, Larry L. Kestin, Benjamin Movsas, George B. Rodrigues, Kenneth E. Rosenzweig, Ben J. Slotman, Igor I. Rybkin, Andrea Wolf, Joe Y. ChangDOI: https://doi.org/10.1016/j.jtho.2020.10.020Vol. 16, Issue 1, p66 75Open AccessAtezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical TrialsJulien Mazieres, Achim Rittmeyer, Shirish Gadgeel, Toyoaki Hida, David R. Gandara, Diego L. Cortinovis, Fabrice Barlesi, Wei Yu, Christina Matheny, Marcus Ballinger, Keunchil ParkDOI: https://doi.org/10.1016/j.jtho.2020.09.022Vol. 16, Issue 1, p140 150Open AccessA 10-Year Cross-Sectional Analysis of Public, Oncologist, and Patient Attitudes About Lung Cancer and Associated StigmaMaureen Rigney, Eleni Rapsomaniki, Lisa Carter-Harris, Jennifer C. KingDOI: https://doi.org/10.1016/j.jtho.2020.09.011Vol. 16, Issue 1, p151 155Open Access Genotype-specific differences in circulating tumor DNA levels in advanced NSCLCVincent K. Lam, Jianjun Zhang, Carol C. Wu, Hai T. Tran, Lerong Li, Lixia Diao, Jing Wang, Waree Rinsurongkawong, Victoria M. Raymond, Richard B. Lanman, Jeff Lewis, Emily B. Roarty, Jack Roth, Stephen Swisher, J. Jack Lee, Don L. Gibbons, Vassiliki A. Papadimitrakopoulou, John V. HeymachDOI: https://doi.org/10.1016/j.jtho.2020.12.011Publication stage: In Press Journal Pre-ProofPDFCharacterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic targetXiuning Le, Marcelo V. Negrao, Alexandre Reuben, Lorenzo Federico, Lixia Diao, Daniel McGrail, Monique Nilsson, Jacqulyne Robichaux, Irene Guijarro Munoz, Sonia Patel, Yasir Elamin, You-Hong Fan, Won-Chul Lee, Edwin Parra, Luisa Maren Solis Soto, Runzhe Chen, Jun Li, Tatiana Karpinets, Roohussaba Khairullah, Humam Kadara, Carmen Behrens, Boris Sepesi, Ruiping Wang, Mingrui Zhu, Linghua Wang, Ara Vaporiciyan, Jack Roth, Steven Swisher, Cara Haymaker, Jianhua Zhang, Jing Wang, Kwok-Kin Wong, Lauren A. Byers, Chantale Bernatchez, Jianjun Zhang, Ignacio I. Wistuba, Don L. Gibbons, Esra A. Akbay, John V. HeymachDOI: https://doi.org/10.1016/j.jtho.2020.12.010Publication stage: In Press Journal Pre-ProofPDFStatistical Considerations for Subgroup AnalysesXiaofei Wang, Steven Piantadosi, Jennifer Le-Rademacher, Sumithra J. MandrekarDOI: https://doi.org/10.1016/j.jtho.2020.12.008Publication stage: In Press Journal Pre-ProofPDFAccuracy and Reproducibility of Intra-Operative Assessment on Tumor Spread Through Air Spaces (STAS) in Stage 1 Lung AdenocarcinomasJulian A. Villalba, Angela R. Shih, Treah May S. Sayo, Keiko Kunitoki, Yin P. Hung, Amy Ly, Marina Kem, Lida P. Hariri, Ashok Muniappan, Henning A. Gaissert, Yolonda L. Colson, Michael D. Lanuti, Mari Mino-KenudsonDOI: https://doi.org/10.1016/j.jtho.2020.12.005Publication stage: In Press Journal Pre-ProofPDFBeyond osimertinib: The development of 3rd-generation EGFR Tyrosine Kinase InhibitorsMisako Nagasaka, Viola W. Zhu, Sun Min Lim, Michael Greco, Fengying Wu, Sai-Hong Ignatius OuDOI: https://doi.org/10.1016/j.jtho.2020.11.028Publication stage: In Press Journal Pre-ProofOpen AccessPDF The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 ClassificationWilliam D. Travis, Elisabeth Brambilla, Andrew G. Nicholson, Yasushi Yatabe, John H.M. Austin, Mary Beth Beasley, Lucian. R. Chirieac, Sanja Dacic, Edwina Duhig, Douglas B. Flieder, Kim Geisinger, Fred R. Hirsch, Yuichi Ishikawa, Keith M. Kerr, Masayuki Noguchi, Giuseppe Pelosi, Charles A. Powell, Ming Sound Tsao, Ignacio Wistuba, On Behalf of the WHO PanelDOI: https://doi.org/10.1097/JTO.0000000000000630Vol. 10, Issue 9, p1243 1260Open ArchiveFull-Text HTMLPDFThe Ras/Raf/MAPK PathwayJulian R. Molina, Alex A. AdjeiDOI: https://doi.org/10.1016/S1556-0864(15)31506-9Vol. 1, Issue 1, p7 9Open ArchiveFull-Text HTMLPDFBeyond osimertinib: The development of 3rd-generation EGFR Tyrosine Kinase InhibitorsMisako Nagasaka, Viola W. Zhu, Sun Min Lim, Michael Greco, Fengying Wu, Sai-Hong Ignatius OuDOI: https://doi.org/10.1016/j.jtho.2020.11.028Publication stage: In Press Journal Pre-ProofOpen AccessPDFPulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung CancerSufang Tian, Weidong Hu, Li Niu, Huan Liu, Haibo Xu, Shu-Yuan XiaoDOI: https://doi.org/10.1016/j.jtho.2020.02.010Vol. 15, Issue 5, p700 704Full-Text HTMLPDFLung Screening Benefits and Challenges: A Review of The Data and Outline for ImplementationJacob Sands, Martin C. Tammemägi, Sebastien Couraud, David R. Baldwin, Andrea Borondy-Kitts, David Yankelevitz, Jennifer Lewis, Fred Grannis, Hans-Ulrich Kauczor, Oyunbileg von Stackelberg, Lecia Sequist, Ugo Pastorino, Brady McKeeDOI: https://doi.org/10.1016/j.jtho.2020.10.127Vol. 16, Issue 1, p37 53Open AccessFull-Text HTMLPDF Image of the Month Figure 1(A) Unenhanced thoracic CT scan revealing enlarged right hilar lymph nodes and bilateral pleural effusion. (B) In the middle zone of both lungs, patchy areas of ground glass that can be referred to the SARS-CoV-2 infection are evident. CT, computed tomography; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. Podcast Listen to JTO Editor Alex Adjei discuss the evolution of the Journal and the impact it has on lung cancer awareness for professionals. Listen Here. About IASLC The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide.

TAGS:Journal Page Home 

<<< Thank you for your visit >>>

Hot Websites